6 days ago · EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria; Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies

3 days ago · AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated intra-abdominal infections (cIAI) and limited treatment options.

3 days ago · AbbVie expects Emblaveo to become available in the third quarter of this year. The company did not reveal its price. “As bacteria evolve, industry, government, and clinical experts must work ...

EMBLAVEO for complicated intra-abdominal infections in adults caused by designated susceptible gram-negative microorganisms. See full Prescribing Information.

6 days ago · AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam ...

6 days ago · The US FDA today approved Emblaveo™ (aztreonam and avibactam; AbbVie), a novel fixed-dose, intravenous antibiotic combination, for the treatment of complicated intra-abdominal infections (cIAI) in adults with limited or no alternative treatment options. 1. The approval marks the first and only monobactam/β-lactamase inhibitor combination available for clinical use in the US.

3 days ago · NORTH CHICAGO - AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/-lactamase inhibitor combination antibiotic.. It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment ...

Aztreonam/avibactam, sold under the brand name Emblaveo (by Pfizer), is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections.

6 days ago · The FDA has approved Abbvie’s aztreonam and avibactam monobactam/β-lactamase inhibitor combination antibiotic therapy, the first of its kind, under the name Emblaveo for treating complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria. 1. Emblaveo was approved in combination with metronidazole, for adult who have limited or no alternative options for ...

3 days ago · The U.S. Food and Drug Administration (FDA) has approved AbbVie’s EMBLAVEO (aztreonam and avibactam) as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections ...